Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CD19 CAR-T cells + anti-CD20 CAR-T cells + anti-CD22 CAR-T cells + chidamide
- Development stage
- Unknown
- Lead developer
- The Affiliated Hospital of Xuzhou Medical University
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Small Molecules
- Administration
- Intravenous, Oral
01
Overview
This combination therapy consists of three distinct chimeric antigen receptor (CAR) T-cell products targeting CD19, CD20, and CD22, administered as a sequential infusion or cocktail, in combination with chidamide (tucidinostat), a selective histone deacetylase (HDAC) inhibitor. Developed by the Affiliated Hospital of Xuzhou Medical University, this regimen is designed to treat refractory or relapsed B-cell malignancies, including B-cell acute lymphoblastic leukemia (B-ALL) and various B-cell lymphomas. The rationale for the triple-target approach is to mitigate immune escape caused by antigen loss, a frequent mechanism of resistance in single-target CAR-T therapies. Chidamide is added to the regimen to potentially upregulate target antigen expression on malignant cells and modulate the tumor microenvironment, thereby enhancing the persistence and cytotoxic efficacy of the CAR-T cells.
- Other names
- anti-CD19 CAR-T cells + anti-CD20 CAR-T cells + anti-CD22 CAR-T cells + XCD19/CD22/CD20 CAR-T cocktail + chidamideSequential infusion of CD19, CD22 and CD20 CAR-T cells plus chidamide
02
Targets
CD19 (B lymphocyte antigen CD19)CD20 (B-lymphocyte antigen CD20)CD22 (Cluster of Differentiation 22)HDAC1 (Histone Deacetylase 1)HDAC10 (Histone Deacetylase 10)HDAC11 (Histone Deacetylase 11)HDAC2 (Histone deacetylase 2)HDAC3 (Histone Deacetylase 3)HDAC8 (Histone Deacetylase 8)
Beyond the preview
Go deeper on anti-CD19 CAR-T cells + anti-CD20 CAR-T cells + anti-CD22 CAR-T cells + chidamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CD19 CAR-T cells + anti-CD20 CAR-T cells + anti-CD22 CAR-T cells + chidamide.